Regeneron Pharmaceuticals, INC Form 4 insider transactions

Kathryn Guarini, a Director of Regeneron Pharmaceuticals, Inc., sold 400 shares of common stock on August 10, 2026 for $800.00 per share.

Regeneron Pharmaceuticals Director Arthur F. Ryan reported the sale of common stock under a pre-arranged trading plan.

Regeneron Pharmaceuticals Director Arthur F. Ryan sold 100 shares of common stock on March 2, 2026, under a pre-arranged 10b5-1 trading plan.

A Regeneron Pharmaceuticals director exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 plan.

Regeneron Pharmaceuticals' SVP Controller, Jason Pitofsky, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Regeneron Pharmaceuticals Director Arthur F. Ryan sold common stock totaling 90 shares on February 9, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Director Bonnie L. Bassler exercised stock options and subsequently sold 1,500 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 plan.

Regeneron Pharmaceuticals Director Craig B. Thompson reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options.

Regeneron Pharmaceuticals Director Huda Y. Zoghbi reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options on January 2, 2026, as part of her compensation.

Regeneron Pharmaceuticals Director George L. Sing reported the acquisition of restricted stock units and non-qualified stock options.

Regeneron Pharmaceuticals director Kathryn Guarini acquired 155 restricted stock units and 1,962 non-qualified stock options on January 2, 2026.

Regeneron Pharmaceuticals Director David P. Schenkein reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options.

Regeneron Pharmaceuticals director Joseph L. Goldstein reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options.

Regeneron Pharmaceuticals Director Arthur F. Ryan acquired 155 restricted stock units and 1,962 non-qualified stock options on January 2, 2026.

Regeneron Pharmaceuticals director N. Anthony Coles acquired 155 restricted stock units and 1,962 non-qualified stock options.

Regeneron Pharmaceuticals Director Michael S. Brown reported the acquisition of restricted stock units and non-qualified stock options, effective January 2, 2026.

Regeneron Pharmaceuticals Director Bonnie L. Bassler acquired 155 restricted stock units and 1,962 non-qualified stock options.

Regeneron Pharmaceuticals Director Christine A. Poon acquired 155 shares of common stock and 1,962 non-qualified stock options in a pre-planned transaction.

Regeneron's Co-Chair, President & CSO George Yancopoulos, reported the future vesting of performance stock units and subsequent sale of shares for tax purposes, scheduled for December 31, 2025.

Regeneron Pharmaceuticals' Co-Chair, President & CEO, Leonard S. Schleifer, reported the vesting of performance stock units and related stock transactions.

Regeneron Pharmaceuticals Director George L. Sing reported exercising stock options and subsequent share dispositions for tax purposes.

Regeneron Pharmaceuticals EVP Daniel P. Van Plew reported the disposition of 2,552 shares of common stock at $701.51 per share for tax withholding.

Regeneron Pharmaceuticals' EVP of Research, Andrew J. Murphy, disposed of 4,229 shares of common stock to cover tax obligations at a price of $701.51 per share.

Regeneron Pharmaceuticals' EVP Commercial, Marion McCourt, disposed of 1,021 shares of common stock at $701.51 per share to cover tax withholding obligations.

Regeneron Pharmaceuticals' Co-Chair, President & CSO George Yancopoulos exercised stock options and subsequently sold shares to cover tax obligations.

Regeneron Pharmaceuticals CEO Leonard S. Schleifer exercised stock options and subsequently sold shares to cover tax obligations.

Regeneron Pharmaceuticals' VP Controller, Jason Pitofsky, received new equity awards including restricted stock and stock options, alongside a related stock disposition.

Regeneron Pharmaceuticals executive Daniel P. Van Plew received significant equity awards, including restricted stock and stock options, while also disposing of shares for tax purposes.

Regeneron Pharmaceuticals' EVP of Research, Andrew J. Murphy, reported the acquisition of restricted stock and non-qualified stock options, alongside a disposition of shares for tax withholding.

Regeneron Pharmaceuticals' EVP Commercial, Marion McCourt, reported the acquisition of restricted stock and non-qualified stock options, alongside a tax-related disposition of common stock.